| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.38▲ | 1.38▲ | 1.36▲ | 1.37▲ | 1.45▼ |
| MA10 | 1.38▲ | 1.36▲ | 1.36▲ | 1.36▲ | 1.58▼ |
| MA20 | 1.36▲ | 1.36▲ | 1.37▲ | 1.45▼ | 2.02▼ |
| MA50 | 1.36▲ | 1.36▲ | 1.37▲ | 1.72▼ | 2.15▼ |
| MA100 | 1.35▲ | 1.35▲ | 1.40▼ | 2.01▼ | 4.25▼ |
| MA200 | 1.35▲ | 1.46▼ | 1.53▼ | 2.04▼ | 9.04▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.002▲ | 0.005▲ | 0.002▲ | 0.015▲ | -0.080▼ |
| RSI | 65.291▲ | 58.476▲ | 54.724▲ | 40.472▼ | 39.804▼ |
| STOCH | 86.667▲ | 98.810▲ | 54.028 | 50.147 | 16.396▼ |
| WILL %R | 0.000▲ | 0.000▲ | -12.500▲ | -62.500 | -94.922▼ |
| CCI | 69.202 | 116.667▲ | 75.833 | -49.539 | -64.605 |
|
Tuesday, November 18, 2025 01:38 PM
Soligenix ( ($SNGX) ) just unveiled an update. Soligenix, Inc. reported that on November 18, 2025, it received confirmation from Nasdaq that it ...
|
|
Monday, November 10, 2025 10:05 AM
SNGX READ THE FULL SNGX RESEARCH REPORT Business Update DMC Confirms No Safety Concerns for Ongoing Phase 3 FLASH2 Trial On October 7, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced that the Data ...
|
|
Friday, November 07, 2025 04:48 AM
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 18/11/25 | 1.30 | 1.39 | 1.30 | 1.37 | 180,489 |
| 17/11/25 | 1.37 | 1.40 | 1.34 | 1.35 | 114,100 |
| 14/11/25 | 1.32 | 1.41 | 1.30 | 1.37 | 89,800 |
| 13/11/25 | 1.39 | 1.40 | 1.25 | 1.38 | 405,500 |
| 12/11/25 | 1.41 | 1.44 | 1.35 | 1.36 | 118,400 |
| 11/11/25 | 1.37 | 1.42 | 1.37 | 1.42 | 158,500 |
| 10/11/25 | 1.42 | 1.44 | 1.36 | 1.36 | 152,700 |
| 07/11/25 | 1.29 | 1.39 | 1.25 | 1.37 | 271,200 |
| 06/11/25 | 1.37 | 1.37 | 1.26 | 1.28 | 285,700 |
| 05/11/25 | 1.31 | 1.38 | 1.31 | 1.38 | 239,500 |
|
|
||||
|
|
||||
|
|